Dabrafenib + LTT462 + Trametinib + LXH254 + TNO155 + Spartalizumab + Tislelizumab

Phase 1Terminated

0 views this week 0 watching💤 Quiet

Interest: 21/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

BRAF V600 Colorectal Cancer

Conditions

BRAF V600 Colorectal Cancer

Trial Timeline

Jul 22, 2020 → Sep 25, 2024

NCT ID

NCT04294160

About Dabrafenib + LTT462 + Trametinib + LXH254 + TNO155 + Spartalizumab + Tislelizumab

Dabrafenib + LTT462 + Trametinib + LXH254 + TNO155 + Spartalizumab + Tislelizumab is a phase 1 stage product being developed by Novartis for BRAF V600 Colorectal Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT04294160. Target conditions include BRAF V600 Colorectal Cancer.

What happened to similar drugs?

0 of 2 similar drugs in BRAF V600 Colorectal Cancer were approved

Approved (0) Terminated (1) Active (1)

🔄Encorafenib + Binimetinib + Cetuximab + Irinotecan + Folinic Acid + 5-FluorouracilOno PharmaceuticalPhase 3

❌Cobimetinib + Atezolizumab + PembrolizumabRochePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04294160	Phase 1	Terminated	Jul 22, 2020	Sep 25, 2024	BRAF V600 Colorectal Cancer

Competing Products

13 competing products in BRAF V600 Colorectal Cancer

See all competitors

Product	Company	Stage	Hype Score
PLX3397 + vemurafenib	Daiichi Sankyo	Phase 1	21
TMZ + E7016	Eisai	Phase 2	27
Encorafenib + Binimetinib + Cetuximab + Irinotecan + Folinic Acid + 5-Fluorouracil	Ono Pharmaceutical	Phase 3	40
encorafenib + Binimetinib + Cetuximab	Ono Pharmaceutical	Phase 2	35
Encorafenib + Cetuximab + FOLFIRI	Merck	Phase 2	35
Tafinlar/Mekinist	Novartis	Pre-clinical	33
BKM120 Combined with Vemurafenib (PLX4032)	Novartis	Phase 1/2	32
Cobimetinib + Atezolizumab + Pembrolizumab	Roche	Phase 3	32
LGX818 + MEK162 + LEE011	Pfizer	Phase 1/2	32
MEK162	Pfizer	Phase 2	35
Encorafenib + Binimetinib + cemiplimab+fianlimab	Regeneron Pharmaceuticals	Phase 2	42
Plixorafenib + Cobicistat 150 MG [Tybost]	Brain Biotech	Phase 1	26
Dabrafenib + Trametinib + Hydroxychloroquine	Brain Biotech	Phase 1/2	26